

# CITATION REPORT

List of articles citing

**Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health**

**DOI: 10.18632/oncotarget.240**  
**Oncotarget, 2011, 2, 135-64.**

**Source:** <https://exaly.com/paper-pdf/87793808/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
485	Lentivirus-mediated RNA interference targeting E2F-1 inhibits human gastric cancer MGC-803 cell growth in vivo. <b>2011</b> , 43, 638-45		13
484	Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. <b>2011</b> , 4, re2		201
483	Aberrant Proliferative and Apoptotic Pathways in Acute Lymphoblastic Leukemia (ALL): Molecular Therapies to Overcome Chemo-Resistance. <b>2011</b> ,		0
482	Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy. <b>2011</b> , 18, 5476-82		49
481	Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells. <i>Oncology Reports</i> , <b>2011</b> , 26, 1581-6	3.5	9
480	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells. <b>2011</b> , 19, 6760-7		12
479	mTOR protein localization is cell cycle-regulated. <b>2011</b> , 10, 3608-10		23
478	Cell-type-dependent thyroid hormone effects on glioma tumor cell lines. <b>2011</b> , 2011, 856050		15
477	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. <b>2011</b> , 10, 3003-15		71
476	Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives. <b>2011</b> , 3, 2478-500		39
475	Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. <b>2012</b> , 18, 555-67		238
474	Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. <b>2012</b> , 97, E898-906		36
473	Activated Ras protein accelerates cell cycle progression to perturb Madin-Darby canine kidney cystogenesis. <b>2012</b> , 287, 31703-11		16
472	Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation. <b>2012</b> , 11, 2100-6		20
471	p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. <b>2012</b> , 11, 4579-88		73
470	The role of S6K1 in ER-positive breast cancer. <b>2012</b> , 11, 3159-65		46
469	Muscarinic type 3 receptor induces cytoprotective signaling in salivary gland cells through epidermal growth factor receptor transactivation. <b>2012</b> , 82, 115-24		15

468	Combined effects of EGFR and Hedgehog signaling pathway inhibition on the proliferation and apoptosis of pancreatic cancer cells. <i>Oncology Reports</i> , <b>2012</b> , 28, 519-26	3.5	13
467	Side-effects of resveratrol in HepG2 cells: reduced pten and increased bcl-xl mRNA expression. <i>Molecular Medicine Reports</i> , <b>2012</b> , 6, 1367-70	2.9	7
466	Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. <b>2012</b> , 19, 3748-62		83
465	New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia. <b>2012</b> , 12, 571-96		10
464	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review). <i>Molecular Medicine Reports</i> , <b>2012</b> , 6, 687-94	2.9	20
463	Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. <b>2012</b> , 17, 205-16		61
462	Role of additional novel therapies in myeloproliferative neoplasms. <b>2012</b> , 26, 959-80		6
461	Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells. <b>2012</b> , 237, 1007-17		34
460	MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. <b>2012</b> , 11, 785-96		153
459	The adenosine A3 receptor agonist CI-IB-MECA induces cell death through Ca <sup>2+</sup> /ROS-dependent down regulation of ERK and Akt in A172 human glioma cells. <b>2012</b> , 37, 2667-77		25
458	Novel approaches to target cancer initiating cells-eliminating the root of the cancer. <i>Advances in Biological Regulation</i> , <b>2012</b> , 52, 249-64	6.2	13
457	Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. <b>2012</b> , 314, 244-55		51
456	Wogonin induces cross-regulation between autophagy and apoptosis via a variety of Akt pathway in human nasopharyngeal carcinoma cells. <b>2012</b> , 113, 3476-85		38
455	Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines. <b>2012</b> , 8, 128		30
454	Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. <b>2012</b> , 5, 16		37
453	Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. <b>2012</b> , 18, 4104-13		151
452	Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. <b>2012</b> , 11, 4344-51		125
451	Controversial aspects of oncogene-induced senescence. <b>2012</b> , 11, 4147-51		29

450	A strategy to improve selectivity and targeting to epithelial-derived cancer cells. <b>2012</b> , 164, 205-12		2
449	The emerging multiple roles of nuclear Akt. <b>2012</b> , 1823, 2168-78		134
448	Targeting BRAFV600E in an inducible murine model of melanoma. <b>2012</b> , 181, 785-94		42
447	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. <i>Oncotarget</i> , <b>2012</b> , 3, 1068-111	3.3	250
446	Biliverdin reductase: more than a namesake - the reductase, its Peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C. <i>Frontiers in Pharmacology</i> , <b>2012</b> , 3, 31	5.6	28
445	Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. <i>Frontiers in Oncology</i> , <b>2012</b> , 2, 15	5.3	42
444	Recent discoveries in the cycling, growing and aging of the p53 field. <b>2012</b> , 4, 887-93		18
443	Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. <i>Oncotarget</i> , <b>2012</b> , 3, 954-87	3.3	214
442	PharmGKB summary: caffeine pathway. <b>2012</b> , 22, 389-95		54
441	Answering the ultimate question "what is the proximal cause of aging?". <b>2012</b> , 4, 861-77		150
440	Screening of Gene Mutations in Lung Cancer for Qualification to Molecularly Targeted Therapies. <b>2012</b> ,		3
439	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. <i>Oncotarget</i> , <b>2012</b> , 3, 1600-14	3.3	60
438	Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. <i>Oncotarget</i> , <b>2012</b> , 3, 236-60,3	3.3	138
437	Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer. <b>2012</b> , 51, 1014-23		36
436	Molecular mechanisms of sorafenib action in liver cancer cells. <b>2012</b> , 11, 2843-55		106
435	Defining the expressed breast cancer kinome. <b>2012</b> , 22, 620-3		21
434	Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. <b>2012</b> , 13, 82-101		2
433	Activation of the PI3K-AKT-mTOR signaling pathway promotes DEHP-induced Hep3B cell proliferation. <b>2013</b> , 59, 325-33		35

432	Molecular Genetics of Pancreatic Cancer. <b>2013</b> ,		1
431	SCF promotes dental pulp progenitor migration, neovascularization, and collagen remodeling - potential applications as a homing factor in dental pulp regeneration. <b>2013</b> , 9, 655-67		46
430	Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059. <b>2013</b> , 18, 1561-73		13
429	Conserved regulation of the Jak/STAT pathway by the endosomal protein asrij maintains stem cell potency. <b>2013</b> , 4, 649-58		32
428	Development of therapeutic combinations targeting major cancer signaling pathways. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1592-605	2.2	194
427	Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110 $\beta$ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors. <b>2013</b> , 37, 697-704		10
426	PI3K Pathway Inhibitors: Better Not Left Alone. <b>2013</b> , 19, 895-906		34
425	Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. <b>2013</b> , 32, 147-62		76
424	Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. <b>2013</b> , 337, 200-9		52
423	A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. <b>2013</b> , 24, 15-29		146
422	The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy. <b>2013</b> , 9, 2877-88		38
421	Isolation of a novel thioflavin S-derived compound that inhibits BAG-1-mediated protein interactions and targets BRAF inhibitor-resistant cell lines. <b>2013</b> , 12, 2400-14		18
420	Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells. <i>Advances in Biological Regulation</i> , <b>2013</b> , 53, 202-10	6.2	38
419	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. <b>2013</b> , 331-372		1
418	EPAC-STX interaction may play a role in neurodevelopment/neurogenesis. <b>2013</b> , 81, 216-8		2
417	Discovery of Predictive Biomarkers for Anticancer Drugs. <b>2013</b> , 21-70		
416	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. <b>2013</b> , 14, 249-56		487
415	Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. <b>2013</b> , 12, 491-500		57

414	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. <b>2013</b> , 39, 935-46	259
413	Cell Death Signaling in Cancer Biology and Treatment. <b>2013</b> ,	1
412	Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. <b>2013</b> , 18, 1165-207	238
411	Biliverdin Reductase: Its Multiple Functions in Cell Signaling and Role in Cytoprotection. <b>2013</b> , 379-440	
410	Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss. <b>2013</b> , 4, 476-85	4
409	WITHDRAWN: Anti-tumor effect of Paeonol via regulating NF- $\kappa$ B, AKT and MAPKs activation: A quick review. <b>2013</b> ,	
408	p-21-Activated kinase 1 mediates gastrin-stimulated proliferation in the colorectal mucosa via multiple signaling pathways. <b>2013</b> , 304, G561-7	8
407	The Synthetic Compound Norcantharidin Induced Apoptosis in Mantle Cell Lymphoma In Vivo and In Vitro through the PI3K-Akt-NF- $\kappa$ B Signaling Pathway. <b>2013</b> , 2013, 461487	22
406	Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. <b>2013</b> , 9, e1003464	82
405	Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer. <b>2013</b> , 18, 933-40	11
404	The PI3K/Akt1 pathway enhances steady-state levels of FANCL. <b>2013</b> , 24, 2582-92	7
403	PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer. <b>2013</b> , 19, 2342-54	48
402	AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers. <b>2013</b> , 133, 21-30	36
401	Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. <b>2013</b> , 65, 1214-56	35
400	Bisebromoamide, an extract from Lyngbya species, induces apoptosis through ERK and mTOR inhibitions in renal cancer cells. <b>2013</b> , 2, 32-9	17
399	Genetic changes in nonepithelial ovarian cancer. <b>2013</b> , 13, 871-82	14
398	Perifosine--a new option in treatment of acute myeloid leukemia?. <b>2013</b> , 22, 1315-27	9
397	The differential effects of wild-type and mutated K-Ras on MST2 signaling are determined by K-Ras activation kinetics. <b>2013</b> , 33, 1859-68	22

396	Minireview: Targeting GPCR Activated ERK Pathways for Drug Discovery. <b>2013</b> , 7, 9-15	54
395	miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. <b>2013</b> , 8, e56824	75
394	Lung cancer cells that survive ionizing radiation show increased integrin $\alpha$ 1- and EGFR-dependent invasiveness. <b>2013</b> , 8, e70905	19
393	Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 54	5-3 25
392	Pleiotropic role of HSF1 in neoplastic transformation. <b>2014</b> , 14, 144-55	35
391	Fatty acid esters of phloridzin induce apoptosis of human liver cancer cells through altered gene expression. <b>2014</b> , 9, e107149	32
390	Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour. <b>2014</b> , 9, e100566	9
389	Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. <b>2014</b> , 9, e113037	33
388	Mini profile of potential anticancer properties of propofol. <b>2014</b> , 9, e114440	20
387	Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. <i>Oncotarget</i> , <b>2014</b> , 5, 2853-63	70
386	PC3-secreted microprotein is a novel chemoattractant protein and functions as a high-affinity ligand for CC chemokine receptor 2. <b>2014</b> , 192, 1878-86	21
385	Predicted 25(OH)D score and colorectal cancer risk according to vitamin D receptor expression. <b>2014</b> , 23, 1628-37	21
384	MicroRNA-141 and microRNA-146b-5p inhibit the prometastatic mesenchymal characteristics through the RNA-binding protein AUF1 targeting the transcription factor ZEB1 and the protein kinase AKT. <b>2014</b> , 289, 31433-47	47
383	Im Fokus: die Blockade mit Kinaseinhibitoren. <b>2014</b> , 17, 48-54	
382	Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. <b>2014</b> , 28, 1687-97	27
381	miR-21 promotes human nucleus pulposus cell proliferation through PTEN/AKT signaling. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 4007-18	6-3 73
380	The Zinc-Sensing Receptor, ZnR/GPR39: Signaling and Significance. <b>2014</b> , 111-133	1
379	Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. <b>2014</b> , 20, 2445-56	76

378	Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86. <b>2014</b> , 14, 853	8
377	In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458. <b>2014</b> , 14, 90	3
376	Predictive factors to targeted treatment in gastrointestinal carcinomas. <b>2014</b> , 14, 151-62	4
375	MEK in cancer and cancer therapy. <i>Pharmacology &amp; Therapeutics</i> , <b>2014</b> , 141, 160-71	13.9 174
374	Molecular therapies in hepatocellular carcinoma: what can we target?. <b>2014</b> , 59, 1688-97	34
373	Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. <b>2014</b> , 73, 525-38	27
372	Akt and Erk1/2 activate the ornithine decarboxylase/polyamine system in cardioprotective ischemic preconditioning in rats: the role of mitochondrial permeability transition pores. <b>2014</b> , 390, 133-42	9
371	Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. <b>2014</b> , 33, 5133-8	32
370	Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells. <b>2014</b> , 12, 1205-15	18
369	Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. <b>2014</b> , 351, 173-81	93
368	Molecular aspects of development and regulation of endometriosis. <b>2014</b> , 12, 50	72
367	Zinc Signals in Cellular Functions and Disorders. <b>2014</b> ,	10
366	A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. <b>2014</b> , 32, 1197-203	20
365	Dequalinium induces cytotoxicity in human leukemia NB4 cells by downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways and potentiation of specific inhibitors of these pathways. <b>2014</b> , 38, 795-803	6
364	The role of NAD(+)-dependent isocitrate dehydrogenase 3 subunit in AFB1 induced liver lesion. <b>2014</b> , 224, 371-9	7
363	MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. <b>2014</b> , 16, 1341-53	98
362	Transforming growth factor- $\beta$ (TGF- $\beta$ ) induces the expression of chondrogenesis-related genes through TGF- $\beta$ receptor II (TGFRII)-AKT-mTOR signaling in primary cultured mouse precartilaginous stem cells. <b>2014</b> , 450, 646-51	16
361	Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors. <b>2014</b> , 24, 3600-4	9



360	Anti-tumor effect of paeonol via regulating NF- $\kappa$ B, AKT and MAPKs activation: A quick review. <b>2014</b> , 4, 9-14		9
359	Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. <i>Oncology Letters</i> , <b>2014</b> , 8, 1249-1254	2.6	28
358	Voltage-dependent anion channel (VDAC-1) is required for olfactory sensing in <i>Caenorhabditis elegans</i> . <b>2015</b> , 20, 802-16		2
357	BLID: A Novel Tumor-Suppressor Gene. <b>2014</b> , 22, 333-8		1
356	Associations of PI3KR1 and mTOR polymorphisms with esophageal squamous cell carcinoma risk and gene-environment interactions in Eastern Chinese populations. <b>2015</b> , 5, 8250		38
355	Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition. <b>2015</b> , 34, 112		38
354	Direkte Modulation von Aktivität und Funktion kleiner GTPasen. <b>2015</b> , 127, 13718-13741		9
353	Direct Modulation of Small GTPase Activity and Function. <b>2015</b> , 54, 13516-37		56
352	Akt and Hippo Pathways in Ewing's Sarcoma Tumors and Their Prognostic Significance. <b>2015</b> , 6, 1005-10		13
351	c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences. <i>Biomedicines</i> , <b>2015</b> , 3, 46-70	4.8	48
350	<i>Ruta graveolens</i> L. induces death of glioblastoma cells and neural progenitors, but not of neurons, via ERK 1/2 and AKT activation. <b>2015</b> , 10, e0118864		26
349	Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia. <b>2015</b> , 10, e0137917		13
348	Potential of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. <b>2015</b> , 10, e0131400		31
347	Biliverdin reductase: a target for cancer therapy?. <i>Frontiers in Pharmacology</i> , <b>2015</b> , 6, 119	5.6	23
346	Signal Transduction Reaction Monitoring Deciphers Site-Specific PI3K-mTOR/MAPK Pathway Dynamics in Oncogene-Induced Senescence. <b>2015</b> , 14, 2906-14		27
345	Raf/MEK/ERK Signaling. <b>2015</b> , 275-305		
344	The Intricate Interplay between Mechanisms Underlying Aging and Cancer. <b>2015</b> , 6, 56-75		22
343	Network-level effects of kinase inhibitors modulate TNF- $\alpha$ -induced apoptosis in the intestinal epithelium. <b>2015</b> , 8, ra129		13

342	Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. <b>2015</b> , 122, 1907-16	46
341	SPAG6 silencing inhibits the growth of the malignant myeloid cell lines SKM-1 and K562 via activating p53 and caspase activation-dependent apoptosis. <b>2015</b> , 46, 649-56	17
340	Caveolin-1 deficiency induces a MEK-ERK1/2-Snail-1-dependent epithelial-mesenchymal transition and fibrosis during peritoneal dialysis. <b>2015</b> , 7, 102-23	54
339	Residence time and kinetic efficiency analysis of extracellular signal-regulated kinase 2 inhibitors. <b>2015</b> , 473, 46-52	3
338	Biomarkers and signaling pathways of colorectal cancer stem cells. <b>2015</b> , 36, 1339-53	29
337	A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. <b>2015</b> , 26, 58-64	91
336	Catechol-O-methyltransferase inhibits colorectal cancer cell proliferation and invasion. <b>2015</b> , 46, 17-23	14
335	Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. <b>2015</b> , 56, 1763-70	25
334	PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?. <b>2015</b> , 15, 51-68	37
333	Conditions Affecting Accuracy of Peripheral Nerve Reinnervation and Functional Recovery. <b>2015</b> , 117-128	1
332	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. <b>2015</b> , 132, 96-168	282
331	Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. <b>2015</b> , 138, 323-31	16
330	Allosteric therapies for lung cancer. <b>2015</b> , 34, 303-12	10
329	KIF2A overexpression and its association with clinicopathologic characteristics and unfavorable prognosis in colorectal cancer. <b>2015</b> , 36, 8895-902	15
328	Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia. <b>2015</b> , 88, 380-9	24
327	Combined ginger extract & Gelam honey modulate Ras/ERK and PI3K/AKT pathway genes in colon cancer HT29 cells. <b>2015</b> , 14, 31	74
326	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. <b>2015</b> , 23, 1386-94	30
325	New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. <b>2015</b> , 26, 1-14	38

324	Trametinib in the treatment of melanoma. <b>2015</b> , 15, 735-47		12
323	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. <b>2015</b> , 26, 2450-6		20
322	The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. <b>2015</b> , 16, 34-42		46
321	The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. <b>2015</b> , 45, 609-23		133
320	BRAF gene: From human cancers to developmental syndromes. <b>2015</b> , 22, 359-73		44
319	Molecular Biology Basics in the Omics Era: Cancer Pathology. <b>2015</b> , 67-99		
318	Differential ERK activation during autophagy induced by europium hydroxide nanorods and trehalose: Maximum clearance of huntingtin aggregates through combined treatment. <b>2015</b> , 73, 160-74		24
317	The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair. <b>2016</b> , 7,		42
316	Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling. <i>Oncotarget</i> , <b>2016</b> , 7, 82820-82835	3-3	19
315	Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. <i>Oncotarget</i> , <b>2016</b> , 7, 15648-61	3-3	11
314	Jujuboside A Protects H9C2 Cells from Isoproterenol-Induced Injury via Activating PI3K/Akt/mTOR Signaling Pathway. <b>2016</b> , 2016, 9593716		14
313	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. <i>Oncotarget</i> , <b>2016</b> , 7, 13886-901	3-3	14
312	Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal. <i>Frontiers in Oncology</i> , <b>2016</b> , 6, 115	5-3	33
311	The Quest for Targets Executing MYC-Dependent Cell Transformation. <i>Frontiers in Oncology</i> , <b>2016</b> , 6, 132	5-3	22
310	EMODIN EFFICACY ON THE AKT, MAPK, ERK AND DNMT EXPRESSION PATTERN DURING DMBA-INDUCED ORAL CARCINOMA IN GOLDEN SYRIAN HAMSTERS. <b>2016</b> , 13, 186-193		5
309	The PI3K/Akt/mTOR Pathway. <b>2016</b> , 128-135		1
308	The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. <i>Oncology Letters</i> , <b>2016</b> , 12, 3045-3050	2.6	139
307	Computational Drug Networks: a computational approach to elucidate drug mode of action and to facilitate drug repositioning for neurodegenerative diseases. <b>2016</b> , 19, 11-17		3

306	Inhibition of BMP and of TGF $\beta$ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death. <b>2016</b> , 15, 27	24
305	MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. <b>2016</b> , 30, 1832-43	56
304	Novel anti-cancer agent myrtucommulone-A and thymoquinone abrogate epithelial-mesenchymal transition in cancer cells mainly through the inhibition of PI3K/AKT signalling axis. <b>2016</b> , 416, 71-84	30
303	Desmethylanhydroicaritin isolated from <i>Sophora flavescens</i> , shows antitumor activities in U87MG cells via inhibiting the proliferation, migration and invasion. <b>2016</b> , 43, 140-8	8
302	Cytokine-like 1 Chemoattracts Monocytes/Macrophages via CCR2. <b>2016</b> , 196, 4090-9	20
301	Inhibition of the Ras/Raf/ERK1/2 Signaling Pathway Restores Cultured Spinal Cord-Injured Neuronal Migration, Adhesion, and Dendritic Spine Development. <b>2016</b> , 41, 2086-96	11
300	A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. <b>2016</b> , 77, 1157-64	16
299	Effects of mutations in Wnt/ $\beta$ -catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. <b>2016</b> , 1863, 2942-2976	101
298	Antitumoral Effect of Hibiscus sabdariffa on Human Squamous Cell Carcinoma and Multiple Myeloma Cells. <b>2016</b> , 68, 1161-70	12
297	Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. <b>2016</b> , 18, 425-35	25
296	Aloe-emodin suppresses esophageal cancer cell TE1 proliferation by inhibiting AKT and ERK phosphorylation. <i>Oncology Letters</i> , <b>2016</b> , 12, 2232-2238	2.6 13
295	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. <b>2016</b> , 101, 941-50	30
294	The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. <b>2016</b> , 58, 108-17	8
293	Autophagy regulates Selumetinib (AZD6244) induced-apoptosis in colorectal cancer cells. <i>European Journal of Medicinal Chemistry</i> , <b>2016</b> , 122, 611-618	6.8 17
292	Overexpression of LRIG1 regulates PTEN via MAPK/MEK signaling pathway in esophageal squamous cell carcinoma. <b>2016</b> , 12, 2045-2052	8
291	Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. <b>2016</b> , 159, 457-67	16
290	Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy. <b>2016</b> , 75, 420-7	27
289	Signaling Mechanisms in l-DOPA-Induced Dyskinesia. <b>2016</b> , 155-185	

288	Tissue mechanics promote IDH1-dependent HIF1 $\alpha$ -enascin C feedback to regulate glioblastoma aggression. <b>2016</b> , 18, 1336-1345	157
287	PTEN negatively regulates mTORC2 formation and signaling in grade IV glioma via Rictor hyperphosphorylation at Thr1135 and direct the mode of action of an mTORC1/2 inhibitor. <b>2016</b> , 5, e227	31
286	Intracellular NF- $\kappa$ B/IL-33 harbors essential roles in Ras-induced cellular transformation by contributing to cyclin D1 protein synthesis. <b>2016</b> , 28, 1025-36	7
285	The PI3K/Akt pathway is involved in procyanidin-mediated suppression of human colorectal cancer cell growth. <b>2016</b> , 55, 2196-2209	23
284	p16(INK4A) inhibits the pro-metastatic potentials of osteosarcoma cells through targeting the ERK pathway and TGF- $\beta$ 1. <b>2016</b> , 55, 525-36	19
283	Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein. <b>2016</b> , 28, 377-383	56
282	PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. <i>European Journal of Medicinal Chemistry</i> , <b>2016</b> , 109, 314-41 <sup>6.8</sup>	296
281	Adenovirus-directed expression of TIPE2 suppresses gastric cancer growth via induction of apoptosis and inhibition of AKT and ERK1/2 signaling. <b>2016</b> , 23, 98-106	30
280	Polymorphisms in the AKT1 and AKT2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population. <b>2016</b> , 20, 666-77	24
279	Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA. <b>2016</b> , 45, 721-5	6
278	Glutamate E15 and E171 are Hotspots in p60TRP-Related Cancer. <b>2016</b> , 34, 64-9	1
277	The role of the PI3K/Akt/mTOR pathway in glial scar formation following spinal cord injury. <b>2016</b> , 278, 27-41	55
276	mTOR Inhibition Beyond Rapalogs. <b>2016</b> , 251-275	0
275	Increased phosphorylation of ERK1/2 is associated with worse chemotherapeutic outcome and a poor prognosis in advanced lung adenocarcinoma. <b>2016</b> , 49, 98-109	6
274	"Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. <b>2016</b> , 98, 3-18	317
273	mTOR Inhibition for Cancer Therapy: Past, Present and Future. <b>2016</b> ,	2
272	Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy. <b>2016</b> , 22, 277-83	14
271	Molecular signalling pathways in canine gliomas. <b>2017</b> , 15, 133-150	20

270	Neuroprotective effects of pretreatment of ginsenoside Rb1 on severe cerebral ischemia-induced injuries in aged mice: Involvement of anti-oxidant signaling. <b>2017</b> , 17, 338-345		42
269	Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects. <i>Advances in Biological Regulation</i> , <b>2017</b> , 64, 39-48	6.2	73
268	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <b>2017</b> , 7, 43013		36
267	Signaling pathways as therapeutic targets in biliary tract cancer. <b>2017</b> , 21, 485-498		3
266	Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells. <i>Translational Oncology</i> , <b>2017</b> , 10, 221-228	4.9	36
265	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic -Mutant Melanoma. <b>2017</b> , 23, 5339-5348		101
264	Role of key genetic mutations on increasing migration of brain cancer cells through confinement. <b>2017</b> , 19, 56		5
263	Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways. <b>2017</b> , 7, 1669		19
262	High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma. <b>2017</b> , 96, 1485-1491		10
261	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic -Mutant Colorectal Cancer. <b>2017</b> , 7, 610-619		132
260	16-Hydroxycyclohexa-3, 13-dien-15, 16-olide inhibits the proliferation and induces mitochondrial-dependent apoptosis through Akt, mTOR, and MEK-ERK pathways in human renal carcinoma cells. <b>2017</b> , 36, 95-107		15
259	Combating subclonal evolution of resistant cancer phenotypes. <b>2017</b> , 8, 1231		79
258	Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPAR $\alpha$ -dependent manner in leukemia cells. <b>2017</b> , 39, 1010428317716501		30
257	Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. <b>2017</b> , 6, 2787-2795		23
256	SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. <b>2017</b> , 28, 3028-3036		16
255	mTOR co-targeting strategies for head and neck cancer therapy. <b>2017</b> , 36, 491-502		34
254	Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis. <b>2017</b> , 48, 225-237		2
253	$\beta$ 1-Integrin promotes tension-dependent mammary epithelial cell invasion by engaging the fibronectin synergy site. <b>2017</b> , 28, 2958-2977		38

252	Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications. <b>2017</b> , 30, 1633-1641		28
251	Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. <b>2017</b> , 35, 616-626		19
250	Adenine Nucleotides Control Proliferation In Vivo of Rat Retinal Progenitors by P2Y Receptor. <b>2017</b> , 54, 5142-5155		6
249	Long-term pre-treatment of antioxidant Ginkgo biloba extract EGb-761 attenuates cerebral-ischemia-induced neuronal damage in aged mice. <b>2017</b> , 85, 256-263		30
248	Naringenin Inhibits Proliferation and Survival of Tamoxifen- Resistant Breast Cancer Cells. <b>2017</b> ,		4
247	Moderate Autophagy Inhibits Vascular Smooth Muscle Cell Senescence to Stabilize Progressed Atherosclerotic Plaque via the mTORC1/ULK1/ATG13 Signal Pathway. <b>2017</b> , 2017, 3018190		36
246	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. <i>Oncotarget</i> , <b>2017</b> , 8, 14221-14250	3-3	68
245	Identification and characterization of HPV-independent cervical cancers. <i>Oncotarget</i> , <b>2017</b> , 8, 13375-13386		54
244	Apoptosis in human liver carcinoma caused by gold nanoparticles in combination with carvedilol is mediated via modulation of MAPK/Akt/mTOR pathway and EGFR/FAAD proteins. <b>2018</b> , 52, 189-200		10
243	MiR-502 mediates esophageal cancer cell TE1 proliferation by promoting AKT phosphorylation. <b>2018</b> , 501, 119-123		20
242	Cutaneous melanoma: From pathogenesis to therapy (Review). <b>2018</b> , 52, 1071-1080		164
241	Codon misreading tRNAs promote tumor growth in mice. <b>2018</b> , 15, 773-786		22
240	Comparative aspects of GnRH-Stimulated signal transduction in the vertebrate pituitary - Contributions from teleost model systems. <b>2018</b> , 463, 142-167		31
239	Design of potent B-Raf inhibitors by multiple copy simulation search strategy. <b>2018</b> , 91, 567-574		3
238	Unraveling the Mechanistic Complexity of the Glomerulocystic Phenotype in Dicer Conditional KO Mice by 2D Gel Electrophoresis Coupled Mass Spectrometry. <b>2018</b> , 12, e1700006		3
237	Is Tubulocystic Renal Cell Carcinoma Real?: Genomic Analysis Confirms the World Health Organization Classification. <b>2018</b> , 20, 28-30		2
236	Patient-derived iPSCs show premature neural differentiation and neuron type-specific phenotypes relevant to neurodevelopment. <b>2018</b> , 23, 1687-1698		13
235	Verbascoside: Identification, Quantification, and Potential Sensitization of Colorectal Cancer Cells to 5-FU by Targeting PI3K/AKT Pathway. <b>2018</b> , 8, 16939		26

234	16-Hydroxycyclohexa-3,13-dien-15,16-olide induces anoikis in human renal cell carcinoma cells: involvement of focal adhesion disassembly and signaling. <b>2018</b> , 11, 7679-7690		5
233	Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. <b>2018</b> , 11, 9081-9089		30
232	Complete inhibition of phosphatase and tensin homolog promotes the normal and oxygen-glucose deprivation/reperfusion-injured PC12 cells to cell death. <b>2018</b> , 10, 83-89		2
231	Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions. <i>Oncology Letters</i> , <b>2018</b> , 16, 5615-5620	2.6	8
230	Estrogen Receptor Beta-Mediated Modulation of Lung Cancer Cell Proliferation by 27-Hydroxycholesterol. <b>2018</b> , 9, 470		16
229	Der Experimentator Zellbiologie. <b>2018</b> ,		3
228	Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. <i>Oncotarget</i> , <b>2018</b> , 9, 8263-8277	3.3	54
227	KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. <b>2018</b> , 13, e0193644		8
226	Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells. <b>2018</b> , 47, 680-693		20
225	MiR-141-3p is upregulated in esophageal squamous cell carcinoma and targets pleckstrin homology domain leucine-rich repeat protein phosphatase-2, a negative regulator of the PI3K/AKT pathway. <b>2018</b> , 501, 507-513		22
224	Role of MAPK/MNK1 signaling in virus replication. <b>2018</b> , 253, 48-61		56
223	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. <b>2018</b> , 143, 2053-2064		44
222	PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation. <b>2018</b> , 8, 9296		11
221	Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activation-dependent apoptosis. <i>Oncology Reports</i> , <b>2018</b> , 40, 1487-1494	3.5	17
220	Benzimidazoisquinoline derivatives inhibit glioblastoma cell proliferation through down-regulating Raf/MEK/ERK and PI3K/AKT pathways. <b>2018</b> , 18, 90		10
219	The Zinc Sensing Receptor, ZnR/GPR39, in Health and Disease. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	61
218	In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma. <b>2018</b> , 13, e0200634		5
217	Mechanistic toxicity of DEHP at environmentally relevant concentrations (ERCs) and ecological risk assessment in the Three Gorges Reservoir Area, China. <b>2018</b> , 242, 1939-1949		18



216	Elaborating the Role of Natural Products on the Regulation of Autophagy and their Potentials in Breast Cancer Therapy. <b>2018</b> , 18, 239-255		5
215	Lipids as Nutraceuticals: A Shift in Paradigm. <b>2018</b> , 51-98		3
214	Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. <b>2018</b> , 18, 812		10
213	Genetic variations in the PI3K/PTEN/AKT/mTOR pathway predict tumor response and disease-free survival in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy and radical surgery. <b>2018</b> , 9, 1067-1077		7
212	BRAF mutation: A promising target in colorectal neuroendocrine carcinoma. <b>2019</b> , 144, 1379-1390		17
211	FOXO1 and ETV6 genes may represent novel regulators of splicing factor expression in cellular senescence. <b>2019</b> , 33, 1086-1097		17
210	IL-18/IL-18BP and IL-22/IL-22BP: Two interrelated couples with therapeutic potential. <b>2019</b> , 63, 109388		18
209	Natural melanoma-derived extracellular vesicles. <b>2019</b> , 59, 251-265		20
208	Systemic therapy for brain metastases. <b>2019</b> , 142, 44-50		25
207	Prioritizing selected PPCPs on the basis of environmental and toxicogenetic concerns: A toxicity estimation to confirmation approach. <b>2019</b> , 380, 120828		24
206	Glandular Neoplasia of the Uterine Cervix and Its Related Lesions. <b>2019</b> , 325-368		1
205	Cervical Glandular Neoplasia: Classification and Staging. <b>2019</b> , 12, 281-313		3
204	Serrated Colorectal Cancer: The Road Less Travelled?. <b>2019</b> , 5, 742-754		14
203	mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both and. <b>2019</b> , 39, 4829-4835		4
202	lncRNA ROR promotes the progression of renal cell carcinoma through the miR-206/VEGF axis. <i>Molecular Medicine Reports</i> , <b>2019</b> , 20, 3782-3792	2.9	12
201	The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 852	5.3	20
200	CX-F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy. <b>2019</b> , 168, 14-25		5
199	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma. <i>Oncotarget</i> , <b>2019</b> , 10, 1850-1859	3.3	12

198	Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. <i>Advances in Biological Regulation</i> , <b>2019</b> , 72, 51-62	6.2	100
197	Serum deprivation-response protein regulates aldehyde dehydrogenase 1 through integrin-linked kinase signaling in endometrioid carcinoma cells. <b>2019</b> , 110, 1804-1813		8
196	CXCR4 and CCR7 Expression in Primary Nodal Diffuse Large B-Cell Lymphoma-A Clinical and Immunohistochemical Study. <b>2019</b> , 357, 302-310		10
195	Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells. <b>2019</b> , 19, 299		14
194	Suppression of CpG-ODN-mediated IFN $\alpha$ and TNF $\alpha$ response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists. <b>2019</b> , 369, 82-89		15
193	TGF- $\beta$ induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR. <b>2019</b> , 18, 3589-3602		32
192	Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib. <b>2019</b> , 2019, 3051945		0
191	JNK-Dependent cJun Phosphorylation Mitigates TGF- $\beta$ and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses. <i>Cells</i> , <b>2019</b> , 8,	7.9	4
190	Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells. <b>2019</b> , 19, 1160		17
189	Regulatory mechanisms of microRNAs in colorectal cancer and colorectal cancer stem cells. <b>2020</b> , 235, 776-789		22
188	Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma. <b>2020</b> , 140, 1045-1053.e6		5
187	Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. <b>2020</b> , 126, 1274-1282		18
186	Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. <b>2020</b> , 76, 112-127		25
185	Genomic Characterization of HPV-related and Gastric-type Endocervical Adenocarcinoma: Correlation With Subtype and Clinical Behavior. <b>2020</b> , 39, 578-586		15
184	Study of fatty acid profiles in fish wastes and in silico evaluation of unsaturated fatty acids for mutant B-Raf kinase inhibition. <b>2020</b> , 43, e13272		1
183	Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts. <b>2020</b> , 67, e28639		0
182	The interaction mechanism between autophagy and apoptosis in colon cancer. <i>Translational Oncology</i> , <b>2020</b> , 13, 100871	4.9	32
181	New insights on the role of autophagy in the pathogenesis and treatment of melanoma. <b>2020</b> , 47, 9021-9032		6

180	Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors. <b>2020</b> , 29, 1389-1406		1
179	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. <b>2020</b> , 12,		28
178	Marine compounds targeting the PI3K/Akt signaling pathway in cancer therapy. <b>2020</b> , 129, 110484		13
177	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with -mutant Solid Tumors. <b>2020</b> , 26, 5102-5112		7
176	Pan-RAF Inhibition Shows Anti-Leukemic Activity in -Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with Mutation. <b>2020</b> , 12,		3
175	Zeaxanthin Induces Apoptosis via ROS-Regulated MAPK and AKT Signaling Pathway in Human Gastric Cancer Cells. <b>2020</b> , 13, 10995-11006		21
174	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <b>2020</b> , 20, 1115-1122		6
173	Berberine inhibits proliferation and induces G0/G1 phase arrest in colorectal cancer cells by downregulating IGF2BP3. <b>2020</b> , 260, 118413		9
172	Antiglioma Potential of Coumarins Combined with Sorafenib. <i>Molecules</i> , <b>2020</b> , 25,	4.8	6
171	Sequential Ras/MAPK and PI3K/AKT/mTOR pathways recruitment drives basal extrusion in the prostate-like gland of <i>Drosophila</i> . <b>2020</b> , 11, 2300		7
170	Targeting ERK-Hippo Interplay in Cancer Therapy. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	8
169	I-BET726 suppresses human skin squamous cell carcinoma cell growth in vitro and in vivo. <b>2020</b> , 11, 318		5
168	miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. <b>2020</b> , 880, 173138		21
167	MiR-29 regulates the function of goat granulosa cell by targeting PTX3 via the PI3K/AKT/mTOR and Erk1/2 signaling pathways. <b>2020</b> , 202, 105722		8
166	Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	17
165	Hydrogen sulfide upregulates miR-16-5p targeting PiK3R1 and RAF1 to inhibit neutrophil extracellular trap formation in chickens. <b>2020</b> , 194, 110412		11
164	Recent progress in antitumor functions of the intracellular antibodies. <b>2020</b> , 25, 1109-1120		5
163	A conjugated mTOR/MEK bifunctional inhibitor as potential polypharmacological anticancer agent: the prototype compound discovery. <b>2020</b> , 29, 519-527		2

162	Characterization of the Golgi scaffold protein PAQR3, and its role in tumor suppression and metabolic pathway compartmentalization. <b>2020</b> , 12, 353-362		5
161	Deeping in the Role of the MAP-Kinases Interacting Kinases (MNKs) in Cancer. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	13
160	Cancer stem cell generation by silenced MAPK enhancing PI3K/AKT signaling. <b>2020</b> , 141, 109742		8
159	Comprehensive Investigation into the Role of Ubiquitin-Conjugating Enzyme E2S in Melanoma Development. <b>2021</b> , 141, 374-384		6
158	Autophagy: a promising therapeutic target for improving mesenchymal stem cell biological functions. <b>2021</b> , 476, 1135-1149		5
157	Recent advances in the management of cutaneous malignant melanoma: our case cohort. <b>2021</b> , 59, 534-545		0
156	Transcriptomic Analysis of Diffuse Intrinsic Pontine Glioma (DIPG) Identifies a Targetable ALDH-Positive Subset of Highly Tumorigenic Cancer Stem-like Cells. <b>2021</b> , 19, 223-239		2
155	MicroRNA-144 promotes remote limb ischemic preconditioning-mediated neuroprotection against ischemic stroke via PTEN/Akt pathway. <b>2021</b> , 121, 95-106		9
154	MAPK signaling pathway-targeted marine compounds in cancer therapy. <b>2021</b> , 147, 3-22		2
153	Research Progress on Regulating LncRNAs of Hepatocellular Carcinoma Stem Cells. <b>2021</b> , 14, 917-927		1
152	Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro. <b>2021</b> , 39, 987-1000		1
151	Transmembrane and coiled-coil domain family 3 (TMCC3) regulates breast cancer stem cell and AKT activation. <b>2021</b> , 40, 2858-2871		0
150	miR-124: A Promising Therapeutic Target for Central Nervous System Injuries and Diseases. <b>2021</b> , 1		2
149	Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling. <b>2021</b> , 10, 350-361		1
148	GSK-3 $\beta$ Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. <i>Cells</i> , <b>2021</b> , 10,	7.9	7
147	Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	6
146	A Review of Epidemiology and Cancer Biology of Malignant Melanoma. <b>2021</b> , 13, e15087		4
145	A network-based method for mechanistic investigation and neuroprotective effect on treatment of tanshinone I against ischemic stroke in mouse. <b>2021</b> , 272, 113923		3

144	Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents. <b>2021</b> , 135, 1545-1556	2
143	ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. <b>2021</b> , 2, 100350	1
142	PML-II regulates ERK and AKT signal activation and IFN $\gamma$ -induced cell death. <b>2021</b> , 19, 70	2
141	Inhibition of spindle and kinetochore associated complex subunit 3 suppresses the proliferation and invasion and induced the apoptosis of cutaneous melanoma by affecting the PI3K/Akt pathway. <b>2021</b> , 35, e22895	1
140	UBA2 promotes the progression of renal cell carcinoma by suppressing the p53 signaling. <b>2021</b> , 1	1
139	Targeted Sequencing Identifies the Genetic Variants Associated with High-altitude Polycythemia in the Tibetan Population. 1	0
138	In vitro anti-cancer effect of marmesin by suppression of PI3K/Akt pathway in esophagus cancer cells. <b>2021</b> , 1	2
137	Sargahydroquinonic acid (SHQA) suppresses cellular senescence through Akt/mTOR signaling pathway. <b>2021</b> , 151, 111406	0
136	An Efficient Second-Generation Manufacturing Process for the pan-RAF Inhibitor Belvarafenib.	2
135	Chemopreventive potential of linalool in targeting lung cancer biomarkers: An in silico & in vitro investigation. <b>2021</b> ,	1
134	Pharmacokinetic properties and anti-proliferative mechanisms of vanillin against acute lymphoblastic leukemia (Jurkat) cells. <b>2021</b> , 142, 82-87	1
133	Oleuropein and skin cancer. <b>2021</b> , 615-623	
132	Signaling pathways in human osteoclasts differentiation: ERK1/2 as a key player. <b>2021</b> , 48, 1243-1254	2
131	Xanthohumol and Structurally Related Prenylflavonoids for Cancer Chemoprevention and Control. <b>2020</b> , 319-350	4
130	Antitumor Monoterpenes. <b>2015</b> , 175-200	2
129	MicroRNA-21 Contributes to Liver Regeneration by Targeting PTEN. <b>2016</b> , 22, 83-91	19
128	Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells. <b>2012</b> , 7, e31729	20
127	Isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/m cell cycle arrest and apoptosis. <b>2012</b> , 7, e36808	35

126	Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. <b>2012</b> , 7, e41347		14
125	K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. <b>2012</b> , 7, e44146		53
124	Establishment of HRAS(G12V) transgenic medaka as a stable tumor model for in vivo screening of anticancer drugs. <b>2013</b> , 8, e54424		10
123	Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN- $\gamma$ <b>2013</b> , 8, e73616		39
122	Functional genetic polymorphisms in PP2A subunit genes confer increased risks of lung cancer in southern and eastern Chinese. <b>2013</b> , 8, e77285		9
121	Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives. <b>2017</b> , 12, e0171840		5
120	Integrin $\alpha$ 1 simultaneously controls EGFR-dependent proliferation and Akt-dependent pro-survival signaling in epidermoid carcinoma cells. <b>2012</b> , 4, 368-74		37
119	New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53 <sup>-/-</sup> mice by delaying carcinogenesis. <b>2012</b> , 4, 715-22		89
118	Telomere length regulation through epidermal growth factor receptor signaling in cancer. <b>2017</b> , 8, 550-558		6
117	Selumetinib produces a central core of apoptosis in breast cancer bone metastases in mice. <b>2014</b> , 1, 821-9		3
116	FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies. <i>Oncotarget</i> , <b>2013</b> , 4, 729-38	3-3	41
115	Healthy CD4 <sup>+</sup> T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 55690-55703	3-3	11
114	The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. <i>Oncotarget</i> , <b>2013</b> , 4, 1496-506	3-3	47
113	DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia. <i>Oncotarget</i> , <b>2013</b> , 4, 1712-20	3-3	20
112	Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. <i>Oncotarget</i> , <b>2013</b> , 4, 1999-2009	3-3	53
111	The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent. <i>Oncotarget</i> , <b>2017</b> , 8, 30151-30161	3-3	9
110	Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. <i>Oncotarget</i> , <b>2014</b> , 5, 1502-14	3-3	54
109	Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications. <i>Oncotarget</i> , <b>2017</b> , 8, 48424-48435	3-3	29

108	Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. <i>Oncotarget</i> , <b>2017</b> , 8, 45898-45917	3-3	10
107	PDGFR $\alpha$ p-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. <i>Oncotarget</i> , <b>2014</b> , 5, 1926-41	3-3	45
106	Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk. <i>Oncotarget</i> , <b>2014</b> , 5, 7431-45	3-3	20
105	LINE-1 couples EMT programming with acquisition of oncogenic phenotypes in human bronchial epithelial cells. <i>Oncotarget</i> , <b>2017</b> , 8, 103828-103842	3-3	12
104	NCOA5 promotes proliferation, migration and invasion of colorectal cancer cells via activation of PI3K/AKT pathway. <i>Oncotarget</i> , <b>2017</b> , 8, 107932-107946	3-3	19
103	RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis. <i>Oncotarget</i> , <b>2014</b> , 5, 6734-45	3-3	45
102	Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. <i>Oncotarget</i> , <b>2011</b> , 2, 109-12	3-3	17
101	The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation. <i>Oncotarget</i> , <b>2018</b> , 9, 31531-31548	3-3	21
100	Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. <i>Oncotarget</i> , <b>2014</b> , 5, 11576-87	3-3	60
99	Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380. <i>Oncotarget</i> , <b>2015</b> , 6, 345-54	3-3	9
98	Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. <i>Oncotarget</i> , <b>2015</b> , 6, 4357-68	3-3	72
97	Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. <i>Oncotarget</i> , <b>2011</b> , 2, 538-50	3-3	69
96	Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. <i>Oncotarget</i> , <b>2011</b> , 2, 610-26	3-3	38
95	Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2015</b> , 6, 6597-610	3-3	23
94	Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis. <i>Oncotarget</i> , <b>2011</b> , 2, 705-12	3-3	25
93	Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. <i>Oncotarget</i> , <b>2012</b> , 3, 78-83	3-3	26
92	Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. <i>Oncotarget</i> , <b>2015</b> , 6, 14472-87	3-3	39
91	Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. <i>Oncotarget</i> , <b>2012</b> , 3, 144-57	3-3	17

90	Novel targeted therapies for mantle cell lymphoma. <i>Oncotarget</i> , <b>2012</b> , 3, 203-11	3-3	31
89	Targeting Mnk3 for cancer therapy. <i>Oncotarget</i> , <b>2012</b> , 3, 118-31	3-3	121
88	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. <i>Oncotarget</i> , <b>2012</b> , 3, 371-94	3-3	98
87	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. <i>Oncotarget</i> , <b>2012</b> , 3, 811-23	3-3	53
86	Beyond proliferation: KLF5 promotes angiogenesis of bladder cancer through directly regulating VEGFA transcription. <i>Oncotarget</i> , <b>2015</b> , 6, 43791-805	3-3	47
85	Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2012</b> , 3, 940-53	3-3	65
84	DAB2IP in cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 3766-76	3-3	40
83	PIK3CA mutations in advanced cancers: characteristics and outcomes. <i>Oncotarget</i> , <b>2012</b> , 3, 1566-75	3-3	71
82	Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BE235 and pan-histone deacetylase inhibitor against human pancreatic cancer. <i>Oncotarget</i> , <b>2012</b> , 3, 1416-27	3-3	40
81	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. <i>Oncotarget</i> , <b>2012</b> , 3, 1615-28	3-3	51
80	Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway. <i>Oncotarget</i> , <b>2012</b> , 3, 1688-99	3-3	10
79	Advances in targeting signal transduction pathways. <i>Oncotarget</i> , <b>2012</b> , 3, 1505-21	3-3	39
78	HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth. <i>Oncotarget</i> , <b>2016</b> , 7, 23594-607	3-3	7
77	CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway. <i>Oncotarget</i> , <b>2016</b> , 7, 27787-801	3-3	41
76	Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. <i>Oncotarget</i> , <b>2012</b> , 3, 1522-32	3-3	21
75	Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. <i>Oncotarget</i> , <b>2012</b> , 3, 1711-24	3-3	35
74	FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. <i>Oncotarget</i> , <b>2016</b> , 7, 52597-52612	3-3	31
73	The Effects of Capsaicin on Gastrointestinal Cancers. <i>Molecules</i> , <b>2020</b> , 26,	4.8	11



72	siRNA targeting of Cdx2 inhibits growth of human gastric cancer MGC-803 cells. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 1903-14	5.6	14
71	Exosomal circular RNA_400068 promotes the development of renal cell carcinoma via the miR-210-5p/SOCS1 axis. <i>Molecular Medicine Reports</i> , <b>2020</b> , 22, 4810-4820	2.9	11
70	Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer. <i>Oncology Letters</i> , <b>2020</b> , 19, 1551-1558	2.6	4
69	Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. <i>Translational Andrology and Urology</i> , <b>2013</b> , 2, 187-96	2.3	56
68	Nuclear Odontogenic Ameloblast-Associated Protein (ODAM) Correlates with Melanoma Sentinel Lymph Node Metastasis. <i>Journal of Cancer Therapy</i> , <b>2013</b> , 04, 1283-1289	0.2	2
67	Anti-angiogenic agents in metastatic colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , <b>2015</b> , 7, 71-86	3.4	17
66	Impact of Cellular Genetic Make-up on Colorectal Cancer Cell Lines Response to Ellagic Acid: Implications of Small Interfering RNA. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2016</b> , 17, 743-8	1.7	12
65	Multiple Intelligence Multimedia Courseware (MIMCO)Based on the Constructivist-Contextual Model for the Learning of Some Chemistry Concepts. <i>International Journal of Future Computer and Communication</i> , <b>2012</b> , 29-31	4.6	1
64	Di(2-ethylhexyl) phthalate (DEHP) and thyroid: biological mechanisms of interference and possible clinical implications. <i>Environmental Science and Pollution Research</i> , <b>2021</b> , 1	5.1	3
63	Role of autophagy in gastric carcinogenesis. <i>World Journal of Gastrointestinal Oncology</i> , <b>2021</b> , 13, 1244-1252	3.6	1
62	The tumor suppression theory of aging. <i>Mechanisms of Ageing and Development</i> , <b>2021</b> , 200, 111583	5.6	2
61	Common docking domain mutation E322K of the ERK2 gene is infrequent in oral squamous cell carcinomas. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2012</b> , 13, 6155-7	1.7	5
60	The Biology of K-Ras Signaling Pathways in Pancreatic Cancer. <b>2013</b> , 83-115		
59	Protein Kinase CK2 in Normal and Malignant Hematopoiesis. 344-362		1
58	Combination Development. <b>2016</b> , 151-174		
57	Molecular mechanisms of neoplasia. <i>Annales Academiae Medicae Silesiensis</i> , <b>2017</b> , 71, 225-245	0.1	
56	Signalwege und zellbasierte Assays. <b>2018</b> , 173-193		
55	RCE-4, a potential anti-cervical cancer drug isolated from <i>Reineckia carnea</i> , induces autophagy via the dual blockade of PI3K and ERK pathways in cervical cancer CaSki cells. <i>International Journal of Molecular Medicine</i> , <b>2020</b> , 45, 245-254	4.4	3

54	Nuclear localization dictates hepatocarcinogenesis suppression by glycine N-methyltransferase. <i>Translational Oncology</i> , <b>2021</b> , 15, 101239	4.9	2
53	Actual research trends in etiology and pathogenesis of endometriosis (a review). <i>Russian Journal of Human Reproduction</i> , <b>2020</b> , 26, 118	0.3	1
52	Screening for differentially-expressed microRNA biomarkers in Saudi colorectal cancer patients by small RNA deep sequencing. <i>International Journal of Molecular Medicine</i> , <b>2019</b> , 44, 2027-2036	4.4	2
51	Cancer stem cells, plasticity, and drug resistance.. <b>2020</b> , 3, 140-148		
50	Liver Regeneration in Acute and Acute-on-Chronic Liver Failure. <b>2020</b> , 65-90		
49	Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells. <i>Archives of Pharmacal Research</i> , <b>2021</b> , 1	6.1	4
48	Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistance. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 321-32	4.4	12
47	PAQR3: a novel tumor suppressor gene. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 2562-8	4.4	11
46	Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines. <i>Canadian Journal of Veterinary Research</i> , <b>2016</b> , 80, 209-16	0.5	8
45	Benefits of ellagic acid from grapes and pomegranates against colorectal cancer. <i>Caspian Journal of Internal Medicine</i> , <b>2017</b> , 8, 226-227	1	4
44	MiR-21 promotes pterygium cell proliferation through the PTEN/AKT pathway. <i>Molecular Vision</i> , <b>2018</b> , 24, 485-494	2.3	10
43	Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy. <i>Cancer Biology and Medicine</i> , <b>2019</b> , 16, 415-434	5.2	9
42	CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
41	Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 113996	6.8	0
40	Potential therapeutic strategies to combat HCC.. <i>Current Molecular Pharmacology</i> , <b>2022</b> ,	3.7	0
39	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma.. <i>Pharmacology &amp; Therapeutics</i> , <b>2022</b> , 108107	13.9	4
38	Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy. <i>Cancer Biology and Medicine</i> , <b>2019</b> , 16, 415-434	5.2	10
37	Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.. <i>Advances in Biological Regulation</i> , <b>2021</b> , 100854	6.2	0

36	Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes and therapeutic options. <b>2022</b> , 337-355		
35	TULP3 silencing suppresses cell proliferation, migration and invasion in gastric cancer via the PTEN/Akt/Snail pathway.. <i>Cancer Treatment and Research Communications</i> , <b>2022</b> , 31, 100551	2	
34	Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeutics.. <i>Medicinal Research Reviews</i> , <b>2022</b> ,	14.4	2
33	anticancer effects of alpelisib against PIK3CA-mutated canine hemangiosarcoma cell lines.. <i>Oncology Reports</i> , <b>2022</b> , 47,	3.5	1
32	Bioluminescent zebrafish transplantation model for drug discovery.		
31	The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression.. <i>Biomedicines</i> , <b>2022</b> , 10,	4.8	5
30	Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: State-of-the-Art Review.. <i>JACC: CardioOncology</i> , <b>2022</b> , 4, 1-18	3.8	1
29	Systemic Therapy for Vascular Anomalies and the Emergence of Genotype-Guided Management.. <i>Dermatologic Clinics</i> , <b>2022</b> , 40, 127-136	4.2	0
28	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102840	2.2	2
27	Computational Pathways Analysis and Personalized Medicine in HER2- Positive Breast Cancer. <i>Current Pharmacogenomics and Personalized Medicine</i> , <b>2022</b> , 19,	0.4	
26	A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib.. <i>Clinical Therapeutics</i> , <b>2022</b> ,	3.5	
25	The Chemopreventive Effects of Polyphenols and Coffee, Based upon a DMBA Mouse Model with microRNA and mTOR Gene Expression Biomarkers.. <i>Cells</i> , <b>2022</b> , 11,	7.9	2
24	Data_Sheet_1.pdf. <b>2018</b> ,		
23	Bioluminescent Zebrafish Transplantation Model for Drug Discovery.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 893655	5.6	0
22	MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/Akt signaling.. <i>Signal Transduction and Targeted Therapy</i> , <b>2022</b> , 7, 147	21	1
21	Cell Communication: Intracellular Pathways The PI3K/Akt/mTOR Pathway. <b>2022</b> ,		
20	Neuroprotective Mechanisms of Ginsenoside Rb1 in Central Nervous System Diseases. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
19	Phosphatase and Tensin Homology Deleted on Chromosome 10 Inhibitors Promote Neural Stem Cell Proliferation and Differentiation. <i>Frontiers in Pharmacology</i> , 13,	5.6	

- 18 Mechanisms for Bile Acids CDCA- and DCA-Stimulated Hepatic Spexin Expression. *Cells*, **2022**, 11, 2159 7.9 0
- 17 Ononin Shows Anticancer Activity Against Laryngeal Cancer via the Inhibition of ERK/JNK/p38 Signaling Pathway. *Frontiers in Oncology*, 12, 53 2
- 16 Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma. **2022**, 8, 0
- 15 Teratoma With Malignant Ectomesenchymoma in the Pineal Region: A Case Report. **2022**, 0
- 14 ALDH6A1 weakens the progression of colon cancer via modulating the RAS/RAF/MEK/ERK pathway in cancer cell lines. **2022**, 842, 146757 0
- 13 Morphological signatures of actin organization in single cells accurately classify genetic perturbations using convolutional neural networks with transfer learning. 0
- 12 Paradoxical downregulation of LPAR3 exerts tumor-promoting activity through autophagy induction in Ras-transformed cells. **2022**, 22, 0
- 11 Computational High-throughput screening and In vitro approaches identify CB-006-3; A novel PI3K-BRAFV600E dual targeted inhibitor against melanoma. **2021**, 29, 305-318 0
- 10 Identification of multi-kinase allosteric inhibitors of oncogenic targets EGFR1, PI3 & BRAF Kinase. **2022**, 19, 0
- 9 Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. **2022**, 3, 2
- 8 Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors. 0
- 7 Resveratrol inhibits glioblastoma cells and chemoresistance progression through blockade P-glycoprotein and targeting AKT/PTEN signaling pathway. **2023**, 376, 110409 0
- 6 Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. **2023**, 161, 114452 0
- 5 Virtual screening, pharmacokinetic, and DFT studies of anticancer compounds as potential kinase inhibitors. **2023**, 18, 933-946 0
- 4 Cannabinol inhibits cell growth and triggers cell cycle arrest and apoptosis in cancer cells. **2023**, 48, 102627 0
- 3 MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers. **2023**, 24, 2782 0
- 2 Tumors and Tumor-Like Lesions of the Cervix. **2023**, 35-170 0
- 1 A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial. 0

